Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Clobazam Clear all

Conditions: Epilepsy
Interventions: Clobazam; Drug
Lead sponsor: Pavel Klein; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions: RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Epilepsy, Epilepsy, Generalized, Seizures
Interventions: Clobazam Low Dose, Clobazam High Dose; Drug
Lead sponsor: Lundbeck LLC; Industry
Eligibility: 2 Years to 30 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 10 more

Conditions: Dravet Syndrome
Interventions: Clobazam, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 1 Year to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more

Conditions: Electrical Status Epilepticus in Sleep
Interventions: ESES treated with clobazam; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado • Boston, Massachusetts

Conditions: Refractory Epilepsy
Interventions: clobazam (Onfi), Initial conversion and titration, Conversion schedule - Week 1, Conversion schedule - Week 2, Conversion schedule - Week 3; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Epilepsy, Epilepsy, Generalized, Seizures
Interventions: Clobazam Low Dose, Clobazam Medium Dose, Clobazam High Dose, Placebo; Drug
Lead sponsor: Lundbeck LLC; Industry
Eligibility: 2 Years to 60 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 34
States / cities: Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Epilepsy, Anxiety
Interventions: Clobazam; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 6 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy
Interventions: perampanel; Drug
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
Interventions: Clobazam, Clonazepam, Lorazepam; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: Dravet Syndrome
Interventions: Clobazam; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • Orlando, Florida + 4 more

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Search by objective public record fields.

Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

Clobazam in Subjects With Lennox-Gastaut Syndrome

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment

Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy

Clobazam in Patients With Lennox-Gastaut Syndrome

Use of Clobazam for Epilepsy and Anxiety

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

YouScript IMPACT Registry